The Sales & Marketing Effectiveness in Chemicals Forum will bring together industry leaders as well as experts responsible and deeply involved in sales and marketing strategies.
Interview with Gian Luca Trinei
Read the interview with Gian Luca Trinei, Chief Compliance Officer Italy, Pfizer.
The stringency of anti-corruption and anti-bribery laws in Europe is starting to resemble or even surpass that of US legislation. What measures is the pharmaceutical industry taking to compensate for the growing number of regulations and initiatives?
The pharmaceutical industry is reacting to the growing number of initiatives through the implementation of Compliance programs which take into consideration – where possible – the multiple anticorruption and/or transparency regulations which are in place in a specific region/country.
A good example is represented by the synergy that exists while producing the FCPA trend analysis and the EFPIA transparency disclosure for several kinds of transactions undertaken with Governmental Officials or Health Care Professionals.
A similar synergy is exploited when a company has to comply with different anti-corruption laws. In our case, we have to respect both FCPA prescriptions while dealing with Governmental Officials and at the same time with local Legislative Decree 231/2001 whose (main) objective is to prevent corruption in the Public Administration.
Although the operational ways in which the two laws pursue a similar objective are quite different, it is possible to review a specific process form both points of view, exploiting controls that could satisfy the need to prevent corruption.
Pharma's reputation continues to suffer, and trust is not just something the industry communicates – it has to be earned through industry action. How do you think the industry could maintain or improve trust?
There are several actions that the Pharmaceutical industry could take to earn better trust from the society where it lives:
· Being transparent and ethical in everyday behavior;
· Being focused and inspired by the patient’s need;
· Considering the needs of all its stakeholders, particularly those of the payers in countries where the health care system has to provide assistance to patients while respecting an increasingly restricted expense budget;
· Engaging in initiatives that could improve life for all citizens and patients; respecting and exceeding the prescription of Environment, Health & Safety laws in the production plant;
All of the above behaviors might help the industry in being perceived not as a group of companies only focused on profits, but as a member of the society where they live who has a great sense of solidarity with the surrounding environment.
Interested in this topic?
Process Scale-Up in Pharma (Solid Dosage Forms)
The major objective of this course is to provide a detailed insight into the practical aspects and approaches of process scale-up for different unit operations and technologies.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
Turning Patient Feedback to Meaningful Resource for Care Delivery
Read the interview with Nasser Al Naimi, Deputy Chief Quality Officer at Hamad Medical Corporation, and Co-Director at Hamad Healthcare Quality Institute, and learn how to turn your data into strategic information to drive patient-family centered care.
Creating & Leading Patient Experience Excellence
Read the full interview with Dr. Ahmed Mohammad Abu-Abah, CEO at King Abdullah BinAbdulaziz University Hospital and gain insight into the creating & leading patient experience excellence.
Excelling in PV is not only about Technical Expertise
For a PV leader, to be successful can look like a daily Herculean work: meeting a crucial mandate to minimize harm to patients, while ensuring that a product is prescribed to the right population, and maintaining the highest level of compliance within a very complex set of worldwide regulations.